ArticleJournal of managed care & specialty pharmacy2025
Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non-small cell lung cancer.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Advancements in Immunotherapy for Lung Cancer: A Meta-Analysis of Clinical Trial Outcomes.The clinical respiratory journal · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough immune checkpoint inhibitors (ICIs) have significantly improved overall survival (OS) for patients with metastatic non-small cell lung cancer (mNSCLC), there is a paucity of comparative effectiveness evidence to inform optimal first-line treatment selection.
objectiveTo compare OS among older patients with mNSCLC who received first-line atezolizumab, nivolumab, or pembrolizumab.
methodsThis retrospective cohort study used the 2014-2020 Surveillance, Epidemiology, and End Results-Medicare data and included patients aged 66 years or older, diagnosed with mNSCLC, and treated with first-line atezolizumab, nivolumab, or pembrolizumab. OS was compared using unadjusted, multivariable-adjusted, and propensity score matching (PSM) Cox proportional hazards models. Sensitivity and subgroup analyses by patient histology (squamous and nonsquamous) were also conducted.
resultsThe study cohort included 4,635 patients, 112 treated with atezolizumab, 251 with nivolumab, and 4,272 with pembrolizumab. Pembrolizumab was associated with a significant survival advantage compared with atezolizumab (multivariable-adjusted hazard ratio [HR], 0.67; 95% CI, 0.53-0.84; PSM HR, 0.69; 95% CI, 0.54-0.87) and nivolumab (multivariable-adjusted HR, 0.83; 95% CI, 0.69-0.99) in both main analyses and sensitivity analyses. The OS difference between nivolumab and atezolizumab was inconclusive (multivariable-adjusted HR, 0.73; 95% CI, 0.46-1.16; PSM HR, 0.65; 95% CI, 0.41-1.04). In subgroup analyses, differences in OS between pembrolizumab and nivolumab were not observed among patients with squamous histology (multivariable-adjusted HR, 0.85; 95% CI, 0.65-1.11; PSM HR, 1.15; 95% CI, 0.89-1.49).
conclusionsIn this population-based study, first-line pembrolizumab was associated with a significant OS benefit compared with atezolizumab and nivolumab among older adults with mNSCLC. For patients with squamous histology, OS differences between pembrolizumab and nivolumab were not observed. These findings support pembrolizumab as the preferred first-line treatment for older patients with mNSCLC, while highlighting the need for further investigation into the effectiveness of nivolumab specifically within squamous histology subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.